Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Date:2/24/2011

THE WOODLANDS, Texas, Feb. 24, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2010.  

"We achieved significant progress in the advancement of our drug pipeline in 2010, led by positive results in clinical trials of LX4211 for type 2 diabetes," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We also reported the results of a Phase 2a trial of LX2931 in rheumatoid arthritis, demonstrating a preliminary signal of efficacy and favorable safety profile that we believe supports exploration of higher doses in future studies."

Key Developments of 2010

  • Lexicon reported positive results from a Phase 2a clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, showing statistically significant and rapid improvements in multiple parameters in patients with type 2 diabetes, including significant reductions of HbA1c within four weeks.  Lexicon also reported positive results from a mechanistic study of a tablet formulation of LX4211, showing significantly increased levels of GLP-1 and PYY, important mediators of glycemic and appetite control.  Lexicon plans to initiate a Phase 2b study of LX4211 around mid-year 2011.
  • Lexicon continued its efforts to develop an improved formulation of LX1031, an inhibitor of tryptophan hydro
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    2. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    3. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    4. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
    5. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
    6. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
    7. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
    8. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
    9. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
    10. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
    11. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... 1, 2014  PTC Therapeutics, Inc. (NASDAQ: ... it approved non-statutory stock options to purchase an aggregate ... new employees. The awards were made pursuant to the ... new hires, employment compensation. The inducement grants ... 2014 and are being made as an inducement material ...
    (Date:8/1/2014)... 2014  With monumental health reform coming into effect, ... language. Clinical efficacy is no longer the sole driver ... like PCORI are directing roughly $1 billion a year ... and environments, the federal healthcare ecosystem is changing, and ... outcomes and managed markets to the right people in ...
    (Date:8/1/2014)... LAVAL, Quebec and NEW YORK ... Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. ... by Allergan, Inc. (NYSE: AGN ) in ... Pershing Square regarding the tender offer rules.  ... an attempt to interfere with shareholders, efforts to call ...
    Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
    ... Reportlinker.com announces that a new market research ... Insulin- Western Europe ... package contains 14 insulin market analyses from ... Denmark, Finland, France, Germany, Ireland, Italy, the ...
    ... Calif., July 31, 2011 Accuray Incorporated ... radiation oncology company, announced today that it will showcase ... TomoTherapy® Radiation Therapy Treatment System in the ... Association of Physicists in Medicine (AAPM)/Canadian Organization of Medical ...
    Cached Medicine Technology:Insulin- Western Europe 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 2Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 3Accuray Symposium Puts Spotlight on Quality Assurance in Radiation Oncology at Joint AAPM/COMP Meeting 4
    (Date:8/1/2014)... Although most people are aware of the need ... is particularly important for women. Changes to hormone levels ... ways. Hormones can affect the blood supply to the ... receive nutrients essential to fight infection. In addition, changing ... produced by plaque bacteria, increasing the risk of inflammation ...
    (Date:8/1/2014)... 02, 2014 The successful development of ... business of Guangdong FODAY Automobile Co.,LTD. As early as ... had already organized an excellent team to develop a ... detailed, in-depth technical plans. The company’s vice president Liming ... the direct involvement of the specific arrangement and the ...
    (Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
    (Date:8/1/2014)... August 01, 2014 Cannabis use among young ... aged 14 to 17 having used marijuana at least once ... their slogan “Say ‘No’ to Drugs, Say ‘Yes to Life,’ ... out to youth this summer with factual information about drugs, ... six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to ...
    (Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) issued ... strokes, heart attacks, and other injuries in men who ... as the transferee judge and ordered what could be ... , As one of his first organizing acts, Judge ... who will move the litigation forward on behalf of ...
    Breaking Medicine News(10 mins):Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2
    ... Dr. Hungerford is ... invasive single as well as double hip replacement procedures. , ... (Vocus) June 29, 2009 -- Noted orthopedic surgeon Marc ... hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. Thomas Whitten, Chief of Orthopedics at ...
    ... the victims of these falls, CDC says , MONDAY, ... 47,000 elderly Americans are treated at hospital emergency departments ... according to a federal government study released Monday. , ... day. , U.S. Centers for Disease Control and Prevention ...
    ... the 1600s quinine was the first effective treatment in the ... commonly used treatment against this devastating disease. But the drug ... can range from sickness and headaches to blindness, deafness and ... knew why. Scientists at The University of Nottingham have ...
    ... emergency departments first sites for savings ... CalRHIO announced today that it has selected the RAND ... measure savings resulting from physicians having secure electronic access to ... The first phase of the initiative will measure savings in ...
    ... N.C., June 29 Carolinas HealthCare System ... growth and development of cardiovascular services in North and South ... Sanger Heart and Vascular Institute (SHVI) represents a ... and Vascular Institute. The Institute will continue serving as a ...
    ... Medicaid Funding Boost Merely Scratches Surface in Terms of Meeting ... In summing up the 2009 session of the Texas ... by Governor Rick Perry, the Texas Health Care Association (THCA) ... ($60 million general revenue) for Medicaid-financed nursing home care, substantially ...
    Cached Medicine News:Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:47,000 Elderly Hurt in Walker, Cane Mishaps Each Year 2Health News:Breakthrough in combating the side effects of quinine 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2
    ... For Excellent Drainage PLUS Greater Patient ... BLAKE Drains are white, radiopaque silicone drains ... a solid core center. Their other components ... extension tubing and an adapter. The drains ...
    Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte...
    Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
    Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: